Gene Editing and Epigenomics Core

项目摘要：基因编辑和表观基因组学核心 C-Sig基因编辑和表观基因组学核心提供当前、新兴和未来的基因编辑和 向中心成员提供表观基因组技术和专业知识。核心的组织和基础设施 提供必要的基因编辑和表观基因组学专业知识以及专门的人员来提供建议、与 提供试剂，并直接支持C-SIG成员实现下述具体目标。这个 CORE将继续由CORE主管斯蒂芬·埃克博士领导，他是一位著名的分子 遗传学家兼基因编辑兼副核心主任塔马斯·奥达格博士，他是 梅奥个体化医学中心(CIM)的表观基因组学计划。CIM表观基因组学 计划开发、实施和验证表观基因组技术，并提供这些方法 调查人员。这一资源将被用来提供对C-Sig更广泛领域的访问 通过C-Sig支持的折扣价格加入最先进的表观基因组方法 技术员(50%全职员工)。 快速发展的基因编辑和表观基因组学学科为研究 基因表达的复杂协调，这是通过一系列机械关系调节的，包括 信号通路、转录因子和染色质包装。配对进行表观基因组学分析 通过基因编辑技术促进的基因研究，极大地增强了对 分子信号通路和环境因素。因此，提供对基因编辑的综合访问 和表观基因组学专业知识、工具和分析，为C-Sig成员提供了一套强大而强大的 支持消化系统疾病相关细胞信号研究的技术。 因此，我们已经确定并将追求以下具体目标：i)提供最先进的基因 C-Sig成员所需的编辑和表观基因组学工具和分析，包括定制质粒， 定制核酸酶和获得表观基因组学分析，包括染色质免疫沉淀与 下一代测序(芯片序列分析)、DNA免疫沉淀测序(DIP-SEQ)；二) 通过将成员连接到基因编辑和表观基因组学相关咨询和 教育机会，如研讨会、杂志俱乐部和会议；iii)建立尖端 用于定制基因组和RNA编辑的分子工具和方法，包括新的DNA碱基编辑程序、新的RNA 编辑工具，以及表位转录组学(RNA修饰分析)。C-Sig基因编辑和 表观基因组学核心服务已被53%的中心成员使用，并支持了29种出版物 在过去的筹资周期中。

PROJECT SUMMARY: GENE EDITING AND EPIGENOMICS CORE The C-SiG Gene Editing and Epigenomics Core provides current, emerging, and future gene editing and epigenomic technologies and expertise to center members. The organization and infrastructure of the core provides essential gene editing and epigenomics expertise and dedicated personnel to advise, interact with, provide reagents, and directly support C-SiG members in pursuit of the Specific Aims described below. The core will continue to be led by the Core Director, Dr. Stephen Ekker, who is a well-established molecular geneticist and gene editor and the Associate Core Director, Dr. Tamas Ordog, who is the founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine (CIM). The CIM Epigenomics Program develops, implements, and validates epigenomic technology and offering these methods to investigators. This resource will be leveraged to provide access to a broader segment of the C-SiG membership to state-of-the-art epigenomic methods at a discounted price, through a C-SiG supported technologist (50% FTE). The rapidly evolving disciplines of gene editing and epigenomics provide powerful tools to investigate the complex coordination of gene expression, which is modulated via a web of mechanistic relationships involving signaling pathways, transcription factors, and chromatin packaging. Epigenomics analysis when paired with genetic studies facilitated by gene editing technologies, greatly enhances identification of contributing molecular signaling pathways and environmental factors. Thus, provision of integrated access to gene editing and epigenomics expertise, tools, and assays, provides C-SiG members with a powerful and robust set of technologies to support digestive disease-related cell signaling research. Accordingly, we have defined and will pursue the following Specific Aims: i) Deliver state-of-the-art gene editing and epigenomics tools and assays that are needed by C-SiG members, including custom plasmids, custom nucleases and access to epigenomics assays including chromatin immunoprecipitation coupled with next generation sequencing (ChIP-seq assays), DNA immunoprecipitation-sequencing-based (DIP-seq); ii) Accelerate research by connecting members to gene editing and epigenomics-related consultation and educational opportunities such as seminars, journal clubs, and conferences; iii) Establish cutting-edge molecular tools and methods for custom genome and RNA editing including new DNA base editors, new RNA editing tools, and for epitranscriptomics (RNA modification assays). The C-SiG Gene Editing and Epigenomics Core services have been used by 53% of Center members and supported 29 publications during the past funding cycle.